培力農本方(1498.HK)暴漲近30% 或受益中藥配方顆粒量價齊升
格隆匯1月3日丨港股中藥概念股集體走強,其中,培力農本方(1498.HK)盤中暴漲近30%報1.05港元,市值4.1億港元。培力農本方主要從事濃縮中藥配方顆粒產品的研發、生產、市場推廣及銷售,是一家致力於中醫藥國際化和現代化的中藥企業。2021年11月1日,中藥配方顆粒國家標準全面實施。有機構稱,現階段已發佈和公示的中藥配方顆粒國家標準有196個;由於新標準對中藥配方顆粒原料質量、生產設備、產品檢測等環節均提出了更高要求,中藥配方顆粒各項成本增長,未來有可能導致執行國標和省標的中藥配方顆粒產品供貨價格有較大幅度上漲,中藥配方顆粒出現供不應求現象,培力農本方或將受益。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.